We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+16.43%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$4.68B
AUM Growth
+$199M
Cap. Flow
-$1.42B
Cap. Flow %
-30.22%
Top 10 Hldgs %
50.13%
Holding
119
New
17
Increased
19
Reduced
10
Closed
18

Top Buys

Rank Stock Value
1
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$29M
2
RVNC
Revance Therapeutics, Inc.
RVNC
+$27.1M
3
APLS
Apellis Pharmaceuticals
APLS
+$27M
4
AMED
Amedisys
AMED
+$25.5M
5
RVMD icon
Revolution Medicines
RVMD
+$22.6M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$52.3M
2
MIRM icon
Mirum Pharmaceuticals
MIRM
+$48.8M
3
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$39.7M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$36.6M
5
CPRX
Catalyst Pharmaceutical
CPRX
+$31.1M

Sector Composition

Rank Sector Weight
1 Healthcare 68.03%
2 Financials 0.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NAMS icon
26
NewAmsterdam Pharma
NAMS
$3.47B
$30.1M 0.64%
2,535,723
– –
DCGO icon
27
DocGo
DCGO
$58.9M
$28.7M 0.61%
3,059,000
– –
APLS
28
DELISTED
Apellis Pharmaceuticals
APLS
$28.5M 0.61%
+313,289
New +$27M
GPCR icon
29
Structure Therapeutics
GPCR
$3.49B
$26.1M 0.56%
627,813
+252,813
+67% +$7.08M
ICPT
30
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$23M 0.49%
+2,077,893
New +$29M
AMLX icon
31
Amylyx Pharmaceuticals
AMLX
$2.05B
$22.7M 0.48%
1,050,198
-934,135
-47% -$25.2M
RVNC
32
DELISTED
Revance Therapeutics, Inc.
RVNC
$22M 0.47%
+870,000
New +$27.1M
ATEC icon
33
Alphatec Holdings
ATEC
$1.27B
$21.4M 0.46%
1,189,648
+142,857
+14% +$2.22M
VTYX
34
DELISTED
Ventyx Biosciences
VTYX
$20.2M 0.43%
617,000
– –
VIGL
35
DELISTED
Vigil Neuroscience
VIGL
$19.3M 0.41%
2,052,010
– –
IRON icon
36
Disc Medicine
IRON
$2.83B
$19.1M 0.41%
+430,000
New +$15.3M
VKTX icon
37
Viking Therapeutics
VKTX
$4.04B
$18.2M 0.39%
1,125,000
– –
DNLI icon
38
Denali Therapeutics
DNLI
$3.67B
$17.6M 0.37%
594,989
– –
TERN
39
DELISTED
Terns Pharmaceuticals
TERN
$16.6M 0.35%
1,898,743
-160,678
-8% -$1.87M
DALS
40
DELISTED
DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
$16.4M 0.35%
1,600,000
– –
DAWN
41
DELISTED
Day One Biopharmaceuticals
DAWN
$15.2M 0.32%
+1,269,992
New +$16.6M
MLYS icon
42
Mineralys Therapeutics
MLYS
$2.35B
$14.3M 0.3%
837,000
+107,979
+15% +$1.61M
LUNG icon
43
Pulmonx
LUNG
$49.4M
$14M 0.3%
1,064,285
-1,338,419
-56% -$16.4M
INSM icon
44
Insmed
INSM
$23.2B
$13.9M 0.3%
658,546
– –
ROIV icon
45
Roivant Sciences
ROIV
$25.2B
$13.7M 0.29%
1,354,974
-395,026
-23% -$3.53M
SLRN
46
DELISTED
ACELYRIN
SLRN
$13.6M 0.29%
+650,000
New +$13.3M
FUSN
47
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$13.2M 0.28%
2,823,000
– –
THRX
48
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$13.1M 0.28%
+1,400,352
New +$13.8M
PRME icon
49
Prime Medicine
PRME
$533M
$13M 0.28%
885,314
– –
ANAB icon
50
AnaptysBio
ANAB
$1.6B
$12.5M 0.27%
613,000
– –
1
2
3 4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q2 2023 Portfolio in Review

As of Q2 2023, Deerfield Management held 119 positions worth $4.68B, up 4.4% from $4.49B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Deerfield Management withdrew a net $1.42B in Q2 2023, closing 18 positions and reducing 10 holdings. Its most notable exit was Mirum Pharmaceuticals, an estimated $48.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, up from 63% a quarter earlier, followed by Financials.

Against the trend, Deerfield Management opened a new position in Intercept Pharmaceuticals, Inc. worth $23M.

  • Deerfield Management's largest Q2 2023 buy was Intercept Pharmaceuticals, Inc.: 2,077,893 shares worth $23M.
  • Deerfield Management added most to Amedisys in Q2 2023, an estimated $25.5M increase.
  • Deerfield Management's biggest Q2 2023 reduction was Neurocrine Biosciences, cutting an estimated $52.3M.
  • Deerfield Management fully exited Mirum Pharmaceuticals in Q2 2023, selling an estimated $48.8M.
  • Deerfield Management's ten largest holdings make up 50% of its $4.68B portfolio in Q2 2023.
  • Deerfield Management opened 17 new positions and closed 18 in Q2 2023.
  • Deerfield Management's portfolio value rose 4.4% quarter-over-quarter to $4.68B.

Based on Deerfield Management's 13F filing for Q2 2023, filed 14 Aug 2023.